首页> 外文期刊>Clinical microbiology and infection: European Society of Clinical Microbiology and Infectious Diseases >The impact of multidrug resistance in healthcare-associated and nosocomial Gram-negative bacteraemia on mortality and length of stay: Cohort study
【24h】

The impact of multidrug resistance in healthcare-associated and nosocomial Gram-negative bacteraemia on mortality and length of stay: Cohort study

机译:卫生保健相关和医院内革兰氏阴性菌血症的多重耐药性对死亡率和住院时间的影响:队列研究

获取原文
获取原文并翻译 | 示例
           

摘要

Multidrug-resistant Gram-negative bacteria (MDR-GNB) are an emerging public health threat. Accurate estimates of their clinical impact are vital for justifying interventions directed towards preventing or managing infections caused by these pathogens. A retrospective observational cohort study was conducted between 1 January 2007 and 31 July 2009, involving subjects with healthcare-associated and nosocomial Gram-negative bacteraemia at two large Singaporean hospitals. Outcomes studied were mortality and length of stay post-onset of bacteraemia in survivors (LOS). There were 675 subjects (301 with MDR-GNB) matching study inclusion criteria. On multivariate analysis, multidrug resistance was not associated with 30-day mortality, but it was independently associated with longer LOS in survivors (coefficient, 0.34; 95% CI, 0.21-0.48; p<0.001). The excess LOS attributable to multidrug resistance after adjustment for confounders was 6.1days. Other independent risk factors for higher mortality included male gender, higher APACHE II score, higher Charlson comorbidity index, intensive care unit stay and presence of concomitant pneumonia. Concomitant urinary tract infection and admission to a surgical discipline were associated with lower risk of mortality. Appropriate empirical antibiotic therapy was neither associated with 30-day mortality nor LOS, although the study was not powered to assess this covariate adequately. Our study adds to existing evidence that multidrug resistance per se is not associated with higher mortality when effective antibiotics are used for definitive therapy. However, its association with longer hospitalization justifies the use of control efforts.
机译:多药耐药革兰氏阴性菌(MDR-GNB)是一种新兴的公共卫生威胁。准确估计其临床影响对于证明针对预防或管理由这些病原体引起的感染的干预措施的合理性至关重要。在2007年1月1日至2009年7月31日期间进行了一项回顾性观察队列研究,研究对象是两家新加坡大型医院的医疗保健相关和医院内革兰氏阴性菌血症患者。研究的结果是存活率(LOS)中菌血症发生后的死亡率和住院时间。有675名受试者(301名MDR-GNB)符合研究纳入标准。在多变量分析中,多药耐药性与30天死亡率无关,但与幸存者中更长的LOS独立相关(系数,0.34; 95%CI,0.21-0.48; p <0.001)。调整混杂因素后,归因于多药耐药性的过量LOS为6.1天。死亡率较高的其他独立危险因素包括男性,APACHE II评分较高,Charlson合并症指数较高,重症监护病房住院和伴发肺炎。并发尿路感染和接受外科手术可降低死亡率。适当的经验性抗生素治疗与30天死亡率和LOS均无关,尽管该研究没有足够的能力来评估该协变量。我们的研究增加了现有证据,表明当使用有效的抗生素进行最终治疗时,多药耐药性本身与较高的死亡率无关。但是,其与更长住院时间的联系证明了采取控制措施的合理性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号